Illumina (NASDAQ:ILMN) Issues Earnings Results, Beats Estimates By $0.26 EPS

Illumina (NASDAQ:ILMN) issued its earnings results on Thursday. The life sciences company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.26, FiscalAI reports. The firm had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. Illumina had a return on equity of 29.41% and a net margin of 19.72%. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.34 earnings per share.

Here are the key takeaways from Illumina’s conference call:

• Strong Q3 performance and raised guidance: Rest-of-world organic revenue grew approximately 5%, operating margin reached 25%, and adjusted EPS was $1.44, ahead of expectations. Illumina raised full-year 2026 revenue guidance to $4.64–$4.66 billion and EPS guidance to $5.40–$5.45.
• Clinical demand and NovaSeq X placements remain robust: The company placed more than 80 NovaSeq X instruments in Q3, with clinical sequencing consumables growing 14% year over year. Illumina said the expanding installed base should support consumables revenue for years and expects clinical consumables growth in the mid-teens for 2026.
• Research and applied sequencing consumables declined 6% in the rest of the world, although management said activity appears to be stabilizing. The NovaSeq X transition is largely complete in research markets, while clinical conversion is expected to reach roughly 80%–85% and continue creating pricing headwinds, though less so in 2027.
• Margins and cash generation improved: Q3 gross margin was 69.4% and free cash flow was $378 million. Illumina expects approximately 23.6% operating margin for full-year 2026 and plans to continue opportunistic share repurchases, with about $1.8 billion remaining under its authorization.
• AI, multi-omics, and data initiatives are emerging growth opportunities: Illumina reported growing interest in its Billion Cell Atlas and BioInsight platform, including from GSK, and expects these offerings to become more visible in the financial results around 2027. Management believes multi-omics and AI-driven biological datasets could provide upside beyond its high-single-digit long-term growth framework, though the timing and scale remain uncertain.

Illumina Stock Down 18.6%

Illumina stock traded down $54.07 during midday trading on Friday, hitting $235.99. 5,389,541 shares of the stock were exchanged, compared to its average volume of 2,361,327. Illumina has a 1 year low of $106.12 and a 1 year high of $309.35. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The firm has a market cap of $35.63 billion, a P/E ratio of 40.62, a P/E/G ratio of 4.11 and a beta of 1.41. The company has a 50 day moving average price of $249.30 and a two-hundred day moving average price of $176.18.

Insiders Place Their Bets

In other news, Director Keith Meister sold 457,858 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the sale, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have sold 2,061,235 shares of company stock valued at $436,356,102. Corporate insiders own 2.90% of the company’s stock.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Sunday, October 11th. Stifel Nicolaus increased their price objective on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Royal Bank Of Canada upped their price target on shares of Illumina from $230.00 to $310.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. TD Cowen increased their price target on Illumina from $210.00 to $270.00 and gave the company a “hold” rating in a report on Tuesday, October 13th. Finally, Stephens lowered Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 price objective on the stock. in a research report on Friday, October 23rd. Nine equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Illumina has an average rating of “Hold” and a consensus price target of $238.53.

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.